Until the PII for TS in adults, I guess each of the "events" seemed to me to be not be a real mover. There are some very early stage stuff: TS in kids, maybe the new compound, and maybe if they get CAH back on track and in to the clinic. Then there is the PIII for Endo that is confirmation, but that everyone expects to be fine. If it's not, we have real problems. This is why it was hard for me to see getting out of the current range (i.e., either pretty early or late that is just a confirmation). I hope you're right about biotech in general. That would help a lot.
That's terrific frogs. Appreciate the time and effort.
I struggle to grasp what's going to move NBIX out of the current range in the next 8-10 months, but I've long since given up on predicting where this thing goes. A lot of risk has been taken out so I'm just trying to be content with that. Good luck.